PCSK9 inhibitors may be associated with improved survival in certain cancer patients undergoing immunotherapy. However, the specific details and context of this potential link are unclear, as reports on various cancer treatments and studies are also being discussed. The relationship between PCSK9 inhibitors and cancer patient outcomes appears to be a topic of ongoing research and investigation.